Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2013-08-08
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to find out how successfully non-small-cell lung cancer
patients are able to give an immune response to injections of the immunotherapeutic product
GSK1572932A, and to find out more about the safety of this treatment. A course of eight
injections will be administered over 21 weeks; including screening for suitability and all
tests, the duration of the study for a patient will be 30-35 weeks. During this period
various tests will be performed, including physical examinations and blood tests. The
Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.